Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Kai Neben, Henk M Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Hans Salwender, Igor W Blau, Katja Weisel, Michael Pfreundschuh, Christof Scheid, Ulrich Dührsen, Walter Lindemann, Ingo G H Schmidt-Wolf, Norma Peter, Christian Teschendorf, Hans Martin, Mathias Haenel, Hans G Derigs, Marc S Raab, Anthony D Ho, Helgi van de Velde, Dirk Hose, Pieter Sonneveld, Hartmut Goldschmidt, Kai Neben, Henk M Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Hans Salwender, Igor W Blau, Katja Weisel, Michael Pfreundschuh, Christof Scheid, Ulrich Dührsen, Walter Lindemann, Ingo G H Schmidt-Wolf, Norma Peter, Christian Teschendorf, Hans Martin, Mathias Haenel, Hans G Derigs, Marc S Raab, Anthony D Ho, Helgi van de Velde, Dirk Hose, Pieter Sonneveld, Hartmut Goldschmidt
Abstract
In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the present study, we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/GMMG-HD4 trial. Because of the 2-arm design of the study, we were able to analyze the effect of a bortezomib-based treatment before and after autologous stem cell transplantation (arm B) compared with standard treatment without bortezomib (arm A). For allanalyzed chromosomal aberrations, progression-free survival (PFS) and overall survival (OS) were at least equal or superior in the bortezomib arm compared with the standard arm. Strikingly, patients with del(17p13) benefited the most from the bortezomib-containing treatment: the median PFS in arm A was 12.0 months and in arm B it was 26.2 months (P = .024); the 3 year-OS for arm A was 17% and for arm B it was 69% (P = .028). After multivariate analysis, del(17p13) was an independent predictor for PFS (P < .0001) and OS (P < .0001) in arm A, whereas no statistically significant effect on PFS (P = .28) or OS (P = .12) was seen in arm B. In conclusion, the adverse impact of del(17p13) on PFS and OS could be significantly reduced by bortezomib-based treatment, suggesting that long-term administration of bortezomib should be recommended for patients carrying del(17p13).
Source: PubMed